Equine infectious diseases 

Zoetis UK Ltd today (8 January 2024) announced further guidance for veterinary surgeons and breeders to manage the 2024 breeding season given the current absence of Equip Artervac. Equip Artervac is a part of the Zoetis Equip range of vaccines. It is indicated for the active immunisation for horses against equine viral arteritis (EVA) to reduce the clinical signs and shedding of the virus in nasal secretions following infection. Following consultation with the Equine Infectious Disease Surveilla

BEVA Council member James Crabtree represented BEVA in discussions along with other equine industry representatives, over a strategy of how best to approach the 2024 breeding season in the face of the ongoing unavailability of Equip Artervac (Zoetis) and confirmation that the vaccine will be unavailable until at least the back end of 2024. Meetings involved Zoetis, DEFRA, members of the Eqiune Infectious Disease Surveilance (EIDS) team, BEVA and representatives of the Thoroughbred Breeding Indu

BEVA Council member James Crabtree represented BEVA in discussions along with other equine industry representatives, over a strategy of how best to approach the 2024 breeding season in the face of the ongoing unavailability of Equip Artervac (Zoetis) and confirmation that the vaccine will be unavailable until at least the back end of 2024. Meetings involved Zoetis, DEFRA, members of the Eqiune Infectious Disease Surveilance (EIDS) team, BEVA and representatives of the Thoroughbred Breeding Indus